TREM-1抑制通过PKCδ/CARD9通路减轻小鼠脑出血后神经炎症
该研究在小鼠脑出血模型中探讨TREM-1的作用,采用基因敲除和选择性抑制剂LP17干预,发现抑制TREM-1可减轻神经行为缺陷和神经炎症,促进M2小胶质细胞极化,部分通过PKCδ/CARD9通路及HMGB1激活TREM-1介导。
要点
- TREM-1敲除或鼻腔给予LP17可减轻脑出血后神经行为缺陷和脑水肿。
- LP17促进M2小胶质细胞极化并减少促炎因子,该效应可被CARD9激活逆转。
- HMGB1与TREM-1相互作用增加,抑制HMGB1可减轻神经炎症,被TREM-1激动抗体逆转。
核心结论
- TREM-1通过调节小胶质细胞极化增强脑出血后神经炎症,部分由PKCδ/CARD9通路及HMGB1激活TREM-1介导。
研究设计与样本
- 研究使用CD1小鼠(n=275),通过自体血注射建立脑出血模型。
- 采用TREM-1敲除CRISPR、选择性TREM-1抑制剂LP17(脑出血后2小时鼻腔给药)、CARD9激活CRISPR、TREM-1激动抗体、PKCδ抑制剂Rottlerin及HMGB1抑制剂甘草酸进行干预。
- 检测指标包括神经行为测试、脑含水量、Western blot、免疫荧光染色和免疫共沉淀。
主要发现
- TREM-1敲除减少脑出血诱导的神经行为缺陷和神经炎症反应。
- 脑出血后HMGB1、TREM-1、PKCδ和CARD9的时间表达增加,TREM-1表达于小胶质细胞。
- 鼻腔给予LP17在脑出血后24和72小时显著降低脑水肿并改善神经行为结局。
- LP17促进M2小胶质细胞极化并减少促炎因子,该效应被CARD9激活CRISPR逆转。
- TREM-1抗体增加神经行为缺陷和促炎因子、减少M2小胶质细胞,该效应被Rottlerin逆转;脑出血后HMGB1与TREM-1相互作用增加,甘草酸减轻神经炎症并促进M2小胶质细胞,被TREM-1抗体逆转。
临床怎么用
- TREM-1可能作为脑出血后神经炎症的潜在干预靶点,LP17鼻腔给药在动物模型中显示改善结局。
- HMGB1-TREM-1-PKCδ/CARD9轴参与小胶质细胞极化调控,提示联合靶向该通路可能减轻继发性脑损伤。
局限性
- 研究为小鼠实验,结果尚未在人体验证。
- 具体分子机制及长期功能结局仍需进一步研究。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND AND PURPOSE: Intracerebral hemorrhage (ICH) is a devastating subtype of stroke with high mortality and disability. Inflammatory response promotes secondary brain injury after ICH. TREM (triggering receptor expressed on myeloid cells)-1 is a key regulator of inflammation. The aim of this study was to evaluate the role of TREM-1 in neuroinflammatory response after ICH in mice. METHODS: CD1 mice (n=275) were used in this study. Mice were subjected to ICH by autologous blood injection. TREM-1 knockout CRISPR was administered intracerebroventricularly to evaluate the role of TREM-1 after ICH. A selective TREM-1 inhibitor, LP17, was administered intranasally 2 hours after ICH. To elucidate TREM-1 signaling pathway, CARD9 (caspase recruitment domain family member 9) activation CRISPR was administered with LP17 and TREM-1 activating anti-mouse TREM-1 monoclonal antibody (mAb) was administered with Rottlerin, a specific PKC (protein kinase C) δ inhibitor. Lastly, to evaluate the role of HMGB1 (high-mobility group box 1) in TREM-1 mediated microglia activation, glycyrrhizin, an inhibitor of HMBG1 was administered with TREM-1 activating mAb. Neurobehavioral test, brain water content, Western blot, immunofluorescence staining, and coimmunoprecipitation was performed. RESULTS: TREM-1 knockout reduced ICH-induced neurobehavioral deficits and neuroinflammatory response. The temporal expression of HMGB1, TREM-1, PKC δ, and CARD9 increased after ICH. TREM-1 was expressed on microglia. Intranasal administration of LP17 significantly decreased brain edema and improved neurobehavioral outcomes at 24 and 72 hours after ICH. LP17 promoted M2 microglia polarization and reduced proinflammatory cytokines after ICH, which was reversed with CARD9 activation CRISPR. TREM-1 mAb increased neurobehavior deficits, proinflammatory cytokines, and reduced M2 microglia after ICH, which was reversed with Rottlerin. HMBG1 interaction with TREM-1 increased after ICH, and glycyrrhizin reduced neuroinflammation and promoted M2 microglia which was reversed with TREM-1 mAb. CONCLUSIONS: This study demonstrated that TREM-1 enhanced neuroinflammation by modulating microglia polarization after ICH, and this regulation was partly mediated via PKC δ/CARD9 signaling pathway and increased HMGB1 activation of TREM-1.
引用
- Lu Q, Liu R, Sherchan P, et al. TREM (Triggering Receptor Expressed on Myeloid Cells)-1 Inhibition Attenuates Neuroinflammation via PKC (Protein Kinase C) δ/CARD9 (Caspase Recruitment Domain Family Member 9) Signaling Pathway After Intracerebral Hemorrhage in Mice. Stroke. 2021. PMID: 33947214. doi:10.1161/STROKEAHA.120.032736
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。